Dyne Therapeutics Names Editas Medicine's Lucera as CFO
Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at ...
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, ...
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it ...
Barron's1d
PDD Holdings Inc. ADR
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251
Dyne Therapeutics (NASDAQ:DYN) on Monday  reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating “unprecedented and sustained functional improvement at ...